Hikma Pharmaceuticals PLC EBIT

The latest EBIT for HIK.L is $1.2B as of June 2026. That compares with $980M in the prior-year period — up 26.7% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Hikma Pharmaceuticals PLC's historical trend and sector peers before judging valuation or financial health.

Over the past year, HIK.L's EBIT moved from $980M to $1.2B — a 26.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Hikma Pharmaceuticals PLC's operating scale or balance-sheet position.

Against its sector companies, HIK.L currently prints $1.2B for EBIT, while the sector average sits near $2.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Hikma Pharmaceuticals PLC's growth, margins, and balance sheet.

A EBIT figure of $1.2B for HIK.L is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting HIK.L's EBIT ($1.2B), review year-over-year change from $980M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.